Home > Archive>Volume 17, Issue 12, 2024 >2276-2281. DOI:10.18240/ijo.2024.12.16
PDF HTML XML Export Cite reminder
Monocyte to high-density lipoprotein cholesterol ratio as a predictor of the activity of thyroid-associated ophthalmopathy
Author:
Corresponding Author:

Feng Jiang. Department of Ophthalmology, Nanjing University Medical School Affiliated Drum Tower Hospital, Nanjing 210000, Jiangsu Province, China. jiangfeng_nj@163.com; Song-Tao Yuan. Department of Ophthalmology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China. songtaoyuan@njmu.edu.cn

Fund Project:

Supported by the Special Fund for Clinical Research of Nanjing Drum Tower Hospital (No.2023-LCYJ-PY-37).

  • Article
    • | |
  • Metrics
    • |
  • Reference [17]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    AIM: To evaluate the relationship between monocyte to high-density lipoprotein cholesterol ratio (MHR) and the disease activity of thyroid-associated ophthalmopathy (TAO). METHODS: A total of 87 patients were classified into two groups based on clinical activity score (CAS) scoring criteria: high CAS group (n=62, the CAS score was ≥3); low CAS group (n=25, the CAS score was <3). In addition, a group of healthy people (n=114) were included to compared the MHR. Proptosis, MHR, average signal intensity ratio (SIR), average lacrimal gland (LG)-SIR, average extraocular muscles (EOM) area from 87 patients with TAO were calculated in magnetic resonance imaging (MRI), and compared between these two groups. Correlation testing was utilized to evaluate the association of parameters among the clinical variables. RESULTS: Patients in high CAS group had a higher proptosis (P=0.041) and MHR (P=0.048). Compared to the healthy group, the MHR in the TAO group was higher (P=0.001). Correlation testing declared that CAS score was strongly associated with proptosis and average SIR, and MHR was positively associated with CAS score, average SIR, and average LG-SIR. The area under the receiver operating characteristic curve (AUC) of MHR was 0.6755. CONCLUSION: MHR, a novel inflammatory biomarker, has a significant association with CAS score and MRI imaging (average SIR and LG-SIR) and it can be a new promising predictor during the active phase of TAO.

    Reference
    1 Perros P, Kendall-Taylor P. Thyroid-associated ophthalmopathy: pathogenesis and clinical management. Baillière’s Clin Endocrinol Metab 1995;9(1):115-135.
    2 Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci 2014;55(3):1735-1748.
    3 Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of graves ophthalmopathy. Med Clin North Am 2012;96(2):311-328.
    4 Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol 2011;22(5):385-390.
    5 Soeters MR, van Zeijl CJ, Boelen A, Kloos R, Saeed P, Vriesendorp TM, Mourits MP. Optimal management of Graves orbitopathy: a multidisciplinary approach. Neth J Med 2011;69(7):302-308.
    6 Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves' Orbitopathy (EUGOGO). The 2016 European thyroid association/European group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 2016;5(1):9-26.
    7 Eckstein A, Schittkowski M, Esser J. Surgical treatment of Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab 2012;26(3):339-358.
    8 Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 1989;73(8):639-644.
    9 Tachibana S, Murakami T, Noguchi H, Noguchi Y, Nakashima A, Ohyabu Y, Noguchi S. Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves’ ophthalmopathy. Endocr J 2010;57(10):853-861.
    10 Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000;21(2): 168-199.
    11 Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol 2001;55(3):283-303.
    12 Liu X, Su Y, Jiang M, Fang S, Huang Y, Li Y, Zhong S, Wang Y, Zhang S, Wu Y, Sun J, Fan X, Zhou H. Application of magnetic resonance imaging in the evaluation of disease activity in Graves’ ophthalmopathy. Endocr Pract 2021;27(3):198-205.
    13 Gagliardo C, Radellini S, Morreale Bubella R, Falanga G, Richiusa P, Vadalà M, Ciresi A, Midiri M, Giordano C. Lacrimal gl⁡慮湤搠⁨摥楲慮扩敡瑴楩捯渠敩灮栠片潲灡慶瑥桳礠⹯⁰偨慴歨⁡䩬䵯数摡⁴卨捹椺†㉡〠ㅳ㥩㭭㍰㕬⡥㐠⥡㩮ㅤ〠㡵ㅳⵥㅦふ㡬㘠⹍㱒扉爠㹢㉩㍯卡敲汫癥慲朠杯楦漠⁤卩ⱳ⁥䅡扳慥琠敡⁣䅴Ⱪ⁶䉩牴畹朮愠汅敵瑲琠慒⁡䝤Ⱪ敬琠′愰氲⸰※倳氰愨琴攩氺攲琱ḳ琸漭Ḳ氱礴洱瀮格潢捲社琱攴†牏慮瑯楥漠ⱓ‬渠敍畡瑥牤潡瀠桁椬氠Ṕ瑡潫ṡ汹祡浭灡栠潙挬礠瑆敵牡慭瑩椠潙‬愠湔摡浡潨湡潳捨祩琠敔Ḭ琠潕Ṫ䡩䐠䱍‬挠桋潡汮敥獯瑫敡爠潙氮†牔慨瑥椠潰⁲慯獧浯慳牴歩散爠獩潰晡⁣灴攠牯楦瀠桴敨牥愠汬⁹慭牰瑨敯牣祹⁴摥椭獴敯愭獭敯楯湣⁹整汥搠敲牡汴祩瀠慩瑮椠敲湥瑳獥⹣⁴䥥湤琠⁰䩡䵣潲汥⁡䵴敩摣†㉨づ㉡つ㬠㑡㙤⡥㍮⥯㩣ㅡ㉲ㅣど⵮ㅯ㉭ㅡ㘮⸠㱍扥牤㸠㉐㑲⁩啮汣甠獐潲祡⁣䕴䬠ⰲ‰䈱漹氻愲琸琨ﰶ爩欺‵혱䘷Ⱝ‵䜲氮‼䵢䙲⸾‱刵攠汍慡瑮楯漠湙‬䈠敓瑨睩敲敡湢⁥琠桋攬†湙潡癭敡汳⁨浩慴牡欠教爬†浥潴渠潡捬礮琠敐⁲瑥潯⁰桥楲条桴⵩摶敥渠獮楥瑵祴⁲汯楰灨潩灬爭潴瑯攭楬湹捰桨潯汣敹獴瑥攠牲潡汴⁩牯愠瑩楳漠⁡愠湰摲⁥獤敩癣整牯楲琠祯⁦椠湳⁵浲當汩瑶楡灬氠敡⁦獴捥汲攠牨潥獰楡獴⹥⁣䅴湯湭⁹䤠湦摯楲愠湨⁥䅰捡慴摯⁣乥敬畬牵潬污⁲㈠っ㉡ひ㭣㉩㍮⡯㍭⥡㨺㈠㝡㔠⵲㉥㝴㥲⹯㱳扰牥㹣㉴㕩⁶塥甠⁡䡮ⱡ偹慳湩杳‮夠ⱁ䱮椠⁓塵Ⱳ⁧娠栲愰‱䈳ⰻ′䠵攸
吲Ⱙ›䐳椰渱札″䠰⸵‮䴼潢湲漾挱礶琠敉瑯潮⁵栠楋杯桳ⵥ摯敧湬獵椠瑈礬†汐楡灺潡灲牬潩琠敁楃測†捋桡潮汢敡獹琠敁爬漠汄⁥牭慩瑲椠潏‮愠獍慮湯⁣楹湴摥攠灣敯湵摮整港瑈⁄牌椠獣歨晬慥捳瑴潥牲晬漠牲⁡灴慩灯椠污汮慤爠祣⁡瑲桤祩牯潶楡摳⁣捵慬牡捲椠湤潩浳慥⹡⁳䩥†䍩汮椠湰⁡䱴慩扥䅴湳愠汷⁩㉴と㈠ㅯ㭢㍳㕴⡲ㅵㅣ⥴㩩敶㉥㐠びㅬ㑥⹥㱰戠牡㹰㉮㙥⁡䰠楳畹塤婲Ɐ坥愺渠条†䩭䵵ⱬ⁴䩩楣⁥奮塴ⱥ⁲娠桳慴潵⁤䑹䈮⸠⁃䵬潩湮漠捁祰瑰敬ⴠ瑔潨⵲桯業杢栠ⵈ摥敭湯獳楴琠礲‰氱椸瀻漲瀴爨漱琩攺椱渳‹挭栱漴水攮猼瑢敲爾漱氷†片慡瑮楪潡楩猠⁓愬猠獇潯捴楴慯琠敁摍†睊楲琬栠⁒瑵桳散⁩灣牡攠獍攬渠捁整慩湮搠⁓獌椬稠敂⁵潴晬⁥瑲栠祁牅漬椠摂⁡湮潡摣畨氠敍‬椠牓牡敨獥灢敫捡瑲椠癁攮†潍景瑯档敹⁴来攭湴摯攭版⹄⁌䰭楣灨楯摬獥⁳䡴敥慲汯瑬栠⁲䑡楴獩㈠ち㉳〠㭡ㄠ㥰⡲ㅯ⥧㩮㍯㙳⹴㱩扣爠㹭㉡㝲䑥慲猠⁩呮Ⱐ⁣剡潲潤獩䩶䍡偳Ᵽ⁵偬慡瑲琠敤物獳潥湡⁳䅥䩳Ⱞ†䝊爠慃癥敬獬†䵐䩨ⱹ⁳䵩畯牬琠栲礰‱券⸻′吳㈳⴨爱攲氩愺砹愲琳椷漭渹′洴愶瀮瀼楢湲朾‱愸渠摙‱晬慭瑡⁺映牔慵挟瑡楮漠湂‬愠獅獲敧獥獮洠敁測琠⃖瑺潫⁡潮戠橂攮挠瑍楯癮敯汣祹⁴煥甭慴湯琭楨晩祧⁨挭汤楥湮楳捩慴汹†慬捩瑰楯癰楲瑯祴⁥楩湮†瑲桡祴物潯椠摡敤礠敳⁹摳楴獥敭慩獣攠㩩慭湵楥渭楩瑮楦慬污晭敡慴獩楯扮椠汩楮瑤祥⁸猺琠異摯祴⹥䕴祩敡⡬䰠潰湡摲⥡㉥ぴㅥ㥲㭳㌠㍦⡯㉲⤠㩴㉨㍥㔠ⵥ㉶㑡㍬⹵ation of disease activity and severity in Graves’ ophthalmopathy? Int Ophthalmol 2024;44(1):154.
    19 Akboga MK, Balci KG, Maden O, Ertem AG, Kirbas O, Yayla C, Acar B, Aras D, Kisacik H, Aydogdu S. Usefulness of monocyte to HDL-cholesterol ratio to predict high SYNTAX score in patients with stable coronary artery disease. Biomark Med 2016;10(4):375-383.
    20 Bolayir A, Gokce SF, Cigdem B, Bolayir HA, Yildiz OK, Bolayir E, Topaktas SA. Monocyte/high-density lipoprotein ratio predicts the mortality in ischemic stroke patients. Neurol Neurochir Pol 2018;52(2):150-155.
    21 Dincgez Cakmak B, Dundar B, Ketenci Gencer F, Aydin BB, Yildiz DE. TWEAK and monocyte to HDL ratio as a predictor of metabolic syndrome in patients with polycystic ovary syndrome. Gynecol Endocrinol 2019;35(1):66-71.
    22 Onalan E. The relationship between monocyte to high-density lipoprotein cholesterol ratio
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Xing-Hong Sun, Xiao-Wen Zhang, Chen Han,/et al.Monocyte to high-density lipoprotein cholesterol ratio as a predictor of the activity of thyroid-associated ophthalmopathy. Int J Ophthalmol, 2024,17(12):2276-2281

Copy
Share
Article Metrics
  • Abstract:46
  • PDF: 176
  • HTML: 0
  • Cited by: 0
Publication History
  • Received:October 01,2023
  • Revised:July 02,2024
  • Online: November 19,2024
You are the 4403166 Visitors
Governing Body：Department of Health, Provincial Government of Shaanxi, China
Organizer：Xi'an Medical Association of China
Address：Room 11707-08, Building 2, Unit 1, Wanda Plaza, No.8 Yanta North Road, Xi'an 710054, Shaanxi Province, China
Fax：(8629)82245172 Phone：(+8629)82245172/82210956
Email：ijopress@163.com
International Journal of Ophthalmology ® 2025 All Rights Reserved   The terms of CC BY-NC-ND 4.0 are applicable to all open access content.